{"organizations": [], "uuid": "2bf0b847299efb5ef986894734a6092ccbe7a1f0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-madrigals-mgl-3196-achieves-primar/brief-madrigals-mgl-3196-achieves-primary-endpoint-in-patients-with-heterozygous-familial-hypercholesterolemia-idUSFWN1PY10K", "country": "US", "domain_rank": 408, "title": "Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.496, "site_type": "news", "published": "2018-02-08T20:01:00.000+02:00", "replies_count": 0, "uuid": "2bf0b847299efb5ef986894734a6092ccbe7a1f0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-madrigals-mgl-3196-achieves-primar/brief-madrigals-mgl-3196-achieves-primary-endpoint-in-patients-with-heterozygous-familial-hypercholesterolemia-idUSFWN1PY10K", "ord_in_thread": 0, "title": "Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia", "locations": [], "entities": {"persons": [{"name": "madrigal", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "madrigal pharmaceuticals inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "madrigal pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - Madrigal Pharmaceuticals Inc:\n* MADRIGALâ€˜S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)\n* MADRIGAL PHARMACEUTICALS- STATISTICALLY SIGNIFICANT IMPROVEMENT ACHIEVED IN REDUCTION OF LDL CHOLESTEROL (LDL-C) WITH MGL-3196 COMPARED TO PLACEBO\n* MADRIGAL PHARMACEUTICALS INC - MGL-3196 WAS WELL TOLERATED IN THE TRIAL AS COMPARED TO PLACEBO\n* MADRIGAL PHARMACEUTICALS- LDL-C LOWERING WAS 28.5% IN MGL-3196 TREATED VERSUS PLACEBO IN PRESPECIFIED GROUP OF PATIENTS WHO DIDNT TOLERATE HIGH INTENSITY STATIN DOSES\n* MADRIGAL PHARMACEUTICALS- THERE WERE 2 SERIOUS ADVERSE EVENTS IN STUDY, BOTH UNRELATED TO TREATMENT, ONE IN A PLACEBO AND ONE IN A DRUG-TREATED PATIENT ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T20:01:00.000+02:00", "crawled": "2018-02-08T14:16:19.031+02:00", "highlightTitle": ""}